NeoAdjuvant Dynamic Marker - Adjusted Personalized Therapy Comparing Trastuzumab-deruxtecan Versus Pacli-/Docetaxel+Carboplatin+Trastuzumab+Pertuzumab in HER2+ Early Breast Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Trastuzumab-deruxtecan (Primary) ; Carboplatin; Docetaxel; Paclitaxel; Pertuzumab; Trastuzumab
Indications Early breast cancer; HER2 positive breast cancer
Focus Therapeutic Use
Acronyms ADAPTHER2-IV; WSG-ADAPT-HER2-IV

04 Jun 2024 Status changed to recruiting, according to Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology
04 Jun 2024 According to Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology, study start was in January 2024 (45 sites, enrollment period 24 months). Estimated trial duration of is 5.5 years.
04 Jun 2024 Trial design presented at the 60th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com